BCL2 and B-cell chronic lymphocytic leukemia: While the modulation of the Bcl-2 family has shown great promise in haematological malignancies, such as Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Lymphoma (SLL), or Acute Myeloid Leukaemia (AML), where Venetoclax (ABT-199) is an approved therapeutic option, the use of BH3 mimetics in solid tumours is less successful.